PPARγ in head and neck cancer prevention

Mauricio Burotto, Eva Szabo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Head and neck cancer is a major source of morbidity and mortality worldwide. Intervention during the early phases of carcinogenesis represents a promising new strategy for curbing the devastating effects of this disease and its primary treatment modalities, surgery and radiation with or without concomitant chemotherapy. This review focuses on the peroxisome proliferator-activated receptor gamma (PPARγ) as a target for chemoprevention of oral cancer. Accumulating data suggest that ligands of PPARγ, which include the thiazolidinedione class of agents approved for the treatment of diabetes, inhibit cancer cell growth in vitro and in animal carcinogenesis models, providing the rationale for testing this approach in populations at risk for head and neck cancer.

Original languageEnglish
Pages (from-to)924-929
Number of pages6
JournalOral Oncology
Issue number10
StatePublished - 1 Oct 2014
Externally publishedYes


  • Head and neck cancer
  • Oral carcinoma
  • PPARγ (peroxisome proliferator-activated receptor γ)
  • Pioglitazone


Dive into the research topics of 'PPARγ in head and neck cancer prevention'. Together they form a unique fingerprint.

Cite this